Pneumonia Testing Market Research Report covers the present scenario and the growth prospects of the Pneumonia Testing Industry for 2017-2021. Pneumonia Testing Market, has been prepared based on an in-depth market analysis with inputs from industry experts.
The report covers the market landscape and its growth prospects over the coming years and discussion of the key vendors effective in this market. To calculate the market size, the report considers the revenue generated from the sales of Pneumonia Testing globally.
For further information on this report, please visit- http://www.marketreportsworld.com/10355677
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Following Companies Are Key Players of the Pneumonia Testing Market:
- Abbott Molecular
- Becton, Dickenson and Company (BD)
- Roche Molecular Diagnostics
- Thermo Fisher Scientific
Other Prominent Vendors of Pneumonia Testing Market Are:
- Beckman Coulter
- Eiken Chemical
- Fast-track diagnostics
One trend in market is increase in adoption of molecular diagnostic testing. Accurate and rapid diagnosis of pneumonia reduces recovery time and healthcare expenditure to a significant extent. Recent advances in molecular diagnostic testing technologies have led to an improvement in the precision, sensitivity, efficiency, and speed of clinical diagnostic procedures. For instance, FilmArray by bioMérieux offers fast, easy, and comprehensive molecular testing technology that integrates sample preparation, amplification, detection, and analysis. The system provides extraction, amplification, and detection in a closed system, which minimizes contamination and provides accurate results. Furthermore, innovations such as automation of immunoassay testing are likely to improve accuracy, speed, and reliability of results, which will also help enhance the popularity and adoption of such tests. Also, vendors are developing products with new and advanced technology to retain their competitive edge in the market. Innovative companies are also developing rapid diagnostic multiplex PCR kits to attract new customer bases, like Fast-track diagnostics’ FTD Bacterial pneumoniae_CAP. AdvanDx’s PNA FISH molecular-based diagnostic platform is the first of its kind that can detect E. coli/K. pneumoniae/P. aeroginosa from blood cultures directly in hours.
Ask Sample PDF of Pneumonia Testing Market Report @ http://www.marketreportsworld.com/enquiry/request-sample/10355677
According to the report, one driver in market is growing popularity of POC testing. POC testing is the new boom in the market because of the decreased time latency between diagnosis and treatment. The advances in POC technology have facilitated data storage, data sharing, and communication with public health agencies. Performing these tests to screen infectious diseases extends the applications of this technology to the community practice setting. For instance, processing accurate data on the prevalence of pneumonia in a community could help restrain inappropriate use of antibiotics and improve the allocation of vaccines to areas with the highest need.
Report also presents Geographical Segmentation analysis of Pneumonia Testing Market of Americas, APAC, EMEA region.
For Any Query, Contact Our Expert @ http://www.marketreportsworld.com/enquiry/pre-order-enquiry/10355677
Further, the report states that one challenge in market is limited detection capability and accuracy. Pneumonia testing, especially the rapid diagnostic kit, in many clinical trials has failed to provide accurate results in comparison with detailed testing. One of the prime reasons for this is that pneumonia can be caused either by bacteria, virus, or fungus. Though the assays used to detect bacterial pneumonia can detect almost all the strains of bacteria, it is rare for them to detect pneumonia caused by RSV. For instance, Alere BinaxNOW Streptococcus pneumoniae Antigen Card can detect S. pneumoniae responsible for CAP, but it cannot detect L. pneumophila responsible for atypical pneumonia for which bioMérieux’s bioNexia Legionella can be used. Hence, it becomes difficult for physicians and healthcare professionals to detect pneumonia and its type accurately before proceeding toward its cure. Due to the limited lifespan of biomolecules, vendors fail to develop rapid diagnostic kits that can offer a high degree of accuracy and withstand the stress associated with environmental changes. Available technologies also may be responsible for decreased sensitivity latest PCR technology has higher sensitivity than older techniques like Western Blotting. Hence the inefficiency of these tests to detect pneumonia accurately and at one go, hinder their market growth significantly.
Key questions answered in Pneumonia Testing market report:
- What will the Pneumonia Testing market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving Pneumonia Testing market?
- What are the challenges to Pneumonia Testing market growth?
- Who are the key vendors in Pneumonia Testing market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
No of Pages: 117
Price of Report: $ 3500 (Single User License)
Purchase Report @ http://www.marketreportsworld.com/purchase/10355677
About Market Reports World:
Market Reports World is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.
Mr. Ameya Pingaley
Market Reports World
+1 408 520 9750
Email – firstname.lastname@example.org